norastemizole

norastemizole

Allergy medicine A nonsedating antihistamine for allergic rhinitis, which is an active metabolite of astemizole–Hismanal® without its cardiac side effects. See Antihistamine.
References in periodicals archive ?
Sepracor's stock suffered because analysts are apparently not convinced Sepracor can market its own drug, norastemizole, alone.
Our progress with levalbuterol, and norastemizole, which is now being tested in a large-scale efficacy trial, demonstrates our success in meeting our milestones and aggressively advancing our drug candidates toward commercialization.
We look forward to continued clinical progress in the third and fourth quarters, as we continue our human studies on compounds such as norastemizole, (R,R)-formoterol, and (S)-oxybutynin.
In a pharmacokinetic and pharmacodynamic study, Sepracor showed that norastemizole has a quick onset of action, is well-tolerated up to 100 mg.
Levalbuterol products will be complemented by our rapid-onset, long-acting beta agonist R,R- eformoterol and our nonsedating antihistamine, norastemizole.
We will continue a rapid pace of clinical and premarket activities in the coming months as Sepracor strengthens the therapeutic value and market potential of our core products: levalbuterol, (R, R) - eformoterol, norastemizole and (S)- oxybutynin," concluded Barberich.
Also, through Phase I/II trials, we have demonstrated that norastemizole, an active metabolite of Hismanal(R), has the potential to be a safe, once-daily, potent nonsedating antihistamine.
With Allegra, Norastemizole becomes the second opportunity to make meaningful improvement to a non-sedating antihistamine through Sepracor's Improved Chemical Entity (ICE) strategy.
Sepracor increased spending for its ICE clinical development programs for R-albuterol, norastemizole and S-oxybutynin.
Norastemizole, a differentiated metabolite of the nonsedating antihistamine, Hismanal, is in Phase I/II trials.
Barberich continued, "For our next-generation antihistamines, we began a second Phase I/II clinical trial on Norastemizole, an active metabolite of J & J's Hismanal, and we formed a partnership with Andrx Corporation to develop a once-a-day formulation of terfenadine carboxylate, an active metabolite of the once-leading allergy therapy, Seldane.
We commenced Phase III trials on R-albuterol, our improved asthma therapy, and began Phase I clinical trials on Norastemizole, our next-generation antihistamine.